Edgewise Therapeutics, Inc.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$167.8M
- Total assets
- $552.6M
- Market cap
- $3.8B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $191.4M
- Operating income
- -$191.4M
- Income tax
- $4.0K
- Net income
- -$167.8M
- EPS (basic)
- $-1.63
- EPS (diluted)
- $-1.63
Balance sheet
- Total assets
- $552.6M
- Current assets
- $543.4M
- Total liabilities
- $30.3M
- Current liabilities
- $27.4M
- Shareholders’ equity
- $522.3M
Cash flow
- Operating cash flow
- -$143.8M
- Investing cash flow
- -$32.8M
- Financing cash flow
- $196.1M
- Net cash flow
- $19.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.8B
- EPS (diluted)
- $-1.63
- Shares outstanding
- 109.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 26, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $167.8M.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Edgewise Therapeutics, Inc..
Write a review
News about Edgewise Therapeutics, Inc.
News & sentiment via Polygon.io
